Revenio Group Oyj

REG1V

Equity

ISIN FI0009010912 / Valor 1304192

NASDAQ Helsinki Ltd, Equities (2025-11-21)

EUR 21.60-2.70%

Revenio Group Oyj
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Revenio Group Oyj is a prominent player in the global ophthalmological device and software market, specializing in diagnostic solutions for eye care. The company offers a range of products under the iCare brand, including intraocular pressure measurement devices, fundus imaging devices, and perimeters, which are essential tools for diagnosing conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Revenio's offerings are designed to be user-friendly and reliable, providing healthcare professionals with efficient digital tools that enhance the quality of eye care. Through its innovative solutions, Revenio supports ophthalmologists in delivering accurate and timely diagnoses, thereby improving patient outcomes in the field of ophthalmology.

Summarized from source with an LLMView SourceSector: Technology

Net Sales Growth

Net sales for Q2 2024 reached EUR 25.4 million, a 14.2% increase compared to EUR 22.3 million in Q2 2023. The currency-adjusted growth was 13.5%.

Operating Profit

The adjusted operating profit was EUR 6.0 million (23.5% of net sales), up by 8.9% year-on-year. The reported operating profit stood at EUR 5.3 million, a 12.6% increase, despite EUR 0.73 million in write-offs related to non-strategic capitalizations.

EBITDA Improvement

EBITDA for the quarter was EUR 7.1 million (27.8% of net sales), reflecting a substantial 25.6% growth compared to EUR 5.6 million in the previous year.

Strong Net Cash Flow

Net cash flow from operations totaled EUR 6.5 million, a significant improvement from EUR -0.2 million in Q2 2023, driven by higher net profit and favorable changes in working capital.